Neuro-Cells®
Spinal Cord Injury (SCI)
Key Facts
About Neuroplast
Neuroplast is a Dutch biotech advancing Neuro-Cells®, a proprietary autologous stem cell therapy targeting the shared pathways of neurodegeneration in conditions like spinal cord injury and dementia. The company is clinical-stage, leveraging orphan drug designations for regulatory acceleration in a multi-billion euro market with high unmet need. Its scalable platform and strong IP position it to potentially transform care for millions of patients lacking effective treatments.
View full company profileAbout Neuroplast
Neuroplast is a Dutch biotech advancing Neuro-Cells®, a proprietary autologous stem cell therapy targeting the shared pathways of neurodegeneration in conditions like spinal cord injury and dementia. The company is clinical-stage, leveraging orphan drug designations for regulatory acceleration in a multi-billion euro market with high unmet need. Its scalable platform and strong IP position it to potentially transform care for millions of patients lacking effective treatments.
View full company profileTherapeutic Areas
Other Spinal Cord Injury (SCI) Drugs
| Drug | Company | Phase |
|---|---|---|
| VEN-201 | Ventoux Biosciences | Pre-clinical |